Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.clim.2020.108450 http://scihub22266oqcxt.onion/10.1016/j.clim.2020.108450 32360516!7189192!32360516     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Immunol 2020 ; 215 (ä): 108450 Nephropedia Template TP {{tp|p=32360516|t=2020. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 |pdf=|usr=}}{{32360516}} gab.com Text The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 JO: Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32360516 #FOAvip Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a "cytokine storm" involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101. Twit Text FOAVip The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 ????Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32360516 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32360516 #FOAvip English Wikipedia <ref>{{Cite pmid|32360516}}</ref> The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 #MMPMID32360516 Mastaglio S; Ruggeri A; Risitano AM; Angelillo P; Yancopoulou D; Mastellos DC; Huber-Lang M; Piemontese S; Assanelli A; Garlanda C; Lambris JD; Ciceri F Clin Immunol 2020[Jun]; 215 (ä): 108450 PMID32360516show ga Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a "cytokine storm" involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101. |Aged[MESH] |Antiviral Agents/therapeutic use[MESH] |Atrial Fibrillation/drug therapy/immunology/pathology/virology[MESH] |Betacoronavirus/*drug effects/immunology/pathogenicity[MESH] |COVID-19[MESH] |Complement Activation/*drug effects[MESH] |Complement C3/*antagonists & inhibitors[MESH] |Complement Inactivating Agents/*therapeutic use[MESH] |Coronavirus Infections/*drug therapy/immunology/pathology/virology[MESH] |Humans[MESH] |Hypercholesterolemia/drug therapy/immunology/pathology/virology[MESH] |Hypertension/drug therapy/immunology/pathology/virology[MESH] |Lung/drug effects/immunology/pathology/virology[MESH] |Male[MESH] |Pandemics[MESH] |Peptides, Cyclic/*therapeutic use[MESH] |Pneumonia, Viral/*drug therapy/immunology/pathology/virology[MESH] |SARS-CoV-2[MESH]The first case of COVID-19 treated with the complement C3 inhibitor AM(epmc).pdf DeepDyve Pubget Overpricing